"transforming the lives of chronic patients with disease modifying & sustainable therapies"
siRNAgen Therapeutics is a seed stage RNAi platform technology company founded in 2019 with lead candidates in fibrosis and dermatology as well as an active and diverse pipeline in CNS, metabolic, inflammatory, infectious, and other indication areas.
Our SAMiRNA platform technology is based on over 20 years of oligonucleotide research from Bioneer, the first biotech company in South Korea.
Han Oh Park
Founder & Chairman
30+ yr experience in biotech & Presidential Advisory Council for 3 presidents
6+ yrs in biotech VC, startups, and commercial drug development
27+ yr experience in preclinical and clinical drug development
SAMiRNA platform technology
Delivery beyond the liver to inflamed, adipogenic, neoplastic tissues in organs such as kidney, lung, skin, brain via various RoA
Safe and efficacious based on human and animal studies
Room temperature stable up to 1-year
Environmentally & financially more sustainable manufacturing & QC
Strong IP (190+ patents and FTO completed in SAMiRNA platform)